Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Declines By 13.7%

Entera Bio Ltd. (NASDAQ:ENTX) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 86,100 shares, a drop of 13.7% from the February 28th total of 99,800 shares. Based on an average trading volume of 114,700 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.3% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research note on Tuesday, March 18th.

Institutional Trading of Entera Bio

A number of institutional investors have recently made changes to their positions in the stock. Parkman Healthcare Partners LLC raised its holdings in shares of Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the last quarter. Perigon Wealth Management LLC purchased a new stake in Entera Bio during the fourth quarter valued at $325,000. Northern Trust Corp purchased a new stake in shares of Entera Bio during the 4th quarter valued at about $450,000. Finally, Knoll Capital Management LLC increased its holdings in Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock valued at $12,470,000 after buying an additional 2,000,000 shares during the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Stock Up 2.1 %

Entera Bio stock traded up $0.04 during trading hours on Wednesday, hitting $1.67. The stock had a trading volume of 4,157 shares, compared to its average volume of 109,820. The stock’s 50-day moving average price is $2.11 and its 200-day moving average price is $2.02. Entera Bio has a 12-month low of $1.41 and a 12-month high of $3.35. The stock has a market capitalization of $59.58 million, a P/E ratio of -6.40 and a beta of 1.62.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. On average, research analysts expect that Entera Bio will post -0.28 EPS for the current fiscal year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.